Kine Sciences

Focus: Kine Sciences is an early-stage Korean biotech founded in 2023, focused on erythroid differentiation regulator 1 (EDR1) targeting therapies for neurology indications. The company is currently in Series A financing with a single lead program in Phase 1 development.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Open Jobs

About Kine Sciences

AI assessmentNot Hiring

No open roles listed right now. Follow Kine Sciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

KINE-101

CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

Phase 1

Clinical Trials (1)

NCT07343310A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP

Phase 1

Help build intelligence for Kine Sciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded biotech with a focused, potentially novel mechanism of action in EDR1 targeting
Early-stage exposure in neurology, a high-value therapeutic area with significant unmet medical need
Seoul-based operations offer potential geographic diversity and access to emerging biotech ecosystem in Korea

Watch Out For

Pre-clinical funding stage with minimal revenue visibility; typical Series A runway is 18–24 months, creating near-term dilution and restructuring risk
Single Phase 1 program (KINE-101) with no published data or peer-reviewed validation yet; mechanism unproven clinically
No active job openings listed, zero employee count transparency, and absence of detailed financial/HR data signal lack of operational transparency

Generated by Claude from Kine Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

KINE-101

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT07324642A Phase 1 MAD Study of KINE-101 in Healthy Volunteers

Phase 1

KINE-101

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT07343323A First-in-Human Study of KINE-101 in Healthy Volunteers

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 3 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

1 pipeline

Marketed

Pipeline